<DOC>
	<DOC>NCT00666198</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first SILDENAFIL(Revatio) should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients need to be administered SILDENAFIL(Revatio) in order to be enrolled in the surveillance. Patients not administered SILDENAFIL(Revatio).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>